DDX nanoparticles-encapsulated IL-12 and RIG-I activating DNA plasmid EG-70
Term · Oncology and biomedicine · MLC-T-ONC-012942
A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) and a retinoic acid-inducible gene I protein (RIG-I; DDX58) activating moiety encapsulated in dually derivatized chitosan (DDX) nanoparticles, with potential immunostimulating and antineoplastic activities. Upon intravesical administration of the DDX nanoparticles-encapsulated IL-12 and RIG-I activating DNA plasmid EG-70, the DDX nanoparticles deliver the IL-12 and RIG-I activating DNA plasmid to the bladder urothelium. This leads to local expression of IL-12 and a RIG-I activating moiety. The increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-lymphocyte (CTL) responses against tumor cells. The RIG-I activating moiety activates the cytosolic RNA receptor RIG-I and induces RIG-I-mediated signaling. This upregulates interferon-alpha (IFN-a) and beta (IFN-b), and induces a potent IFN-mediated innate immune response against the tumor cells. This further induces the activation of NKs and CTLs and induces apoptosis in cancer cells.
| Identifier | MLC-T-ONC-012942 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | dually derivatized chitosan nanoparticles-encapsulated IL-12 and RIG-I activating DNA plasmid EG-70 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012942",
"term": "DDX nanoparticles-encapsulated IL-12 and RIG-I activating DNA plasmid EG-70",
"field": "Oncology and biomedicine",
"definition": "A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) and a retinoic acid-inducible gene I protein (RIG-I; DDX58) activating moiety encapsulated in dually derivatized chitosan (DDX) nanoparticles, with potential immunostimulating and antineoplastic activities. Upon intravesical administration of the DDX nanoparticles-encapsulated IL-12 and RIG-I activating DNA plasmid EG-70, the DDX nanoparticles deliver the IL-12 and RIG-I activating DNA plasmid to the bladder urothelium. This leads to local expression of IL-12 and a RIG-I activating moiety. The increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-lymphocyte (CTL) responses against tumor cells. The RIG-I activating moiety activates the cytosolic RNA receptor RIG-I and induces RIG-I-mediated signaling. This upregulates interferon-alpha (IFN-a) and beta (IFN-b), and induces a potent IFN-mediated innate immune response against the tumor cells. This further induces the activation of NKs and CTLs and induces apoptosis in cancer cells.",
"synonyms": [
"dually derivatized chitosan nanoparticles-encapsulated IL-12 and RIG-I activating DNA plasmid EG-70"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/ddx-nanoparticles-encapsulated-il-12-and-rig-i-activating-dna-plasmid-eg-70/"
}
Record 5,740 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.